Cyclophilin inhibitors as a novel HCV therapy

Viruses

Volumn 2, Issue 8, 2010, Pages 1621-1634

  Tang, Hengli ^a  

^a FLORIDA STATE UNIVERSITY   (United States)

Author keywords

Cyclophilins; Cyclosporine A; HCV replication; Immunosuppression; Nonstructural protein 5A 5B

Indexed keywords

ALISPORIVIR; ALPHA INTERFERON; CYCLOPHILIN A; CYCLOPHILIN INHIBITOR; CYCLOSPORIN A; CYCLOSPORIN A [4 N METHYLISOLEUCINE]; CYCLOSPORIN A DERIVATIVE; CYCLOSPORIN D; INTERFERON; NONSTRUCTURAL PROTEIN 5; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN; SANGLIFEHRIN A; SCY 635; TACROLIMUS; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SENSITIVITY; DRUG STRUCTURE; GRAFT REJECTION; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; RNA INTERFERENCE; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANIMALIA; HEPATITIS C VIRUS;

EID: 79952127405     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v2081621     Document Type: Review

References (71)

1. Kuritzkes, D.R. HIV-1 entry inhibitors: an overview. Curr. Opin. HIV AIDS 2009, 4, 82-87.
2. Liu, J.; Farmer, J.D., Jr.; Lane, W.S.; Friedman, J.; Weissman, I.; Schreiber, S.L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991, 66, 807-815.
3. Teraoka, S.; Mishiro, S.; Ebihara, K.; Sanaka, T.; Yamaguchi, Y.; Nakajima, I.; Kawai, T.; Yagisawa, T.; Honda, H.; Fuchinoue, S.; et al. Effect of cyclosporine on proliferation of non-A, non-B hepatitis virus. Transplant Proc. 1988, 20, 868-876.
4. Feinstone, S.M.; Kapikian, A.Z.; Purcell, R.H.; Alter, H.J.; Holland, P.V. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N. Engl. J. Med. 1975, 292, 767-770.
5. Watashi, K.; Hijikata, M.; Hosaka, M.; Yamaji, M.; Shimotohno, K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003, 38, 1282-1288.
6. Nakagawa, M.; Sakamoto, N.; Enomoto, N.; Tanabe, Y.; Kanazawa, N.; Koyama, T.; Kurosaki, M.; Maekawa, S.; Yamashiro, T.; Chen, C.H.; Itsui, Y.; Kakinuma, S.; Watanabe, M. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem. Biophys. Res. Commun. 2004, 313, 42-47.
7. Hilgard, P.; Kahraman, A.; Lehmann, N.; Seltmann, C.; Beckebaum, S.; Ross, R.S.; Baba, H.A.; Malago, M.; Broelsch, C.E.; Gerken, G. Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation: effects on virus replication and recurrent hepatitis. World J. Gastroenterol. 2006, 12, 697-702.
8. Martin, P.; Busuttil, R.W.; Goldstein, R.M.; Crippin, J.S.; Klintmalm, G.B.; Fitzsimmons, W.E.; Uleman, C. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl. 2004, 10, 1258-1262.
9. Guitard, J.; Sandres-Saune, K.; Kamar, N.; Ribes, D.; Faguer, S.; Esposito, L.; Lavit, M.; Muscari, F.; Peron, J.M.; Lavayssiere, L.; Durand, D.; Rostaing, L. Hepatitis C virus viral load after conversion from tacrolimus to cyclosporine in liver transplant patients: a pilot study. Transplant Proc. 2007, 39, 2603-2605.
10. Rayhill, S.C.; Barbeito, R.; Katz, D.; Voigt, M.; Labrecque, D.; Kirby, P.; Miller, R.; Stolpen, A.; Wu, Y.; Schmidt, W. A cyclosporine-based immunosuppressive regimen may be better than tacrolimus for long-term liver allograft survival in recipients transplanted for hepatitis C. Transplant Proc. 2006, 38, 3625-3628.
11. Firpi, R.J.; Zhu, H.; Morelli, G.; Abdelmalek, M.F.; Soldevila-Pico, C.; Machicao, V.I.; Cabrera, R.; Reed, A.I.; Liu, C.; Nelson, D.R. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl. 2006, 12, 51-57.
12. Zervos, X.A.; Weppler, D.; Fragulidis, G.P.; Torres, M.B.; Nery, J.R.; Khan, M.F.; Pinna, A.D.; Kato, T.; Miller, J.; Reddy, K.R.; Tzakis, A.G. Comparison of tacrolimus with neoral as primary immunosuppression in hepatitis C patients after liver transplantation. Transplant Proc. 1998, 30, 1405-1406.
13. Firpi, R.J.; Soldevila-Pico, C.; Morelli, G.G.; Cabrera, R.; Levy, C.; Clark, V.C.; Suman, A.; Michaels, A.; Chen, C.; Nelson, D.R. The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study. Dig. Dis. Sci. 2010, 55, 196-203.
14. Inoue, K.; Sekiyama, K.; Yamada, M.; Watanabe, T.; Yasuda, H.; Yoshiba, M. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J. Gastroenterol. 2003, 38, 567-572.
15. Inoue, K.; Yoshiba, M. Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease. Transplant Proc. 2005, 37, 1233-1234.
16. Paeshuyse, J.; Kaul, A.; De Clercq, E.; Rosenwirth, B.; Dumont, J.M.; Scalfaro, P.; Bartenschlager, R.; Neyts, J. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 2006, 43, 761-770.
17. Inoue, K.; Umehara, T.; Ruegg, U.T.; Yasui, F.; Watanabe, T.; Yasuda, H.; Dumont, J.M.; Scalfaro, P.; Yoshiba, M.; Kohara, M. Evaluation of a cyclophilin inhibitor in hepatitis C virusinfected chimeric mice in vivo. Hepatology 2007, 45, 921-928.
18. Coelmont, L.; Kaptein, S.; Paeshuyse, J.; Vliegen, I.; Dumont, J.M.; Vuagniaux, G.; Neyts, J. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob. Agents Chemother. 2009, 53, 967-976.
19. Flisiak, R.; Feinman, S.V.; Jablkowski, M.; Horban, A.; Kryczka, W.; Pawlowska, M.; Heathcote, J.E.; Mazzella, G.; Vandelli, C.; Nicolas-Metral, V.; Grosgurin, P.; Liz, J.S.; Scalfaro, P.; Porchet, H.; Crabbe, R. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 2009, 49, 1460-1468.
20. Ma, S.; Boerner, J.E.; TiongYip, C.; Weidmann, B.; Ryder, N.S.; Cooreman, M.P.; Lin, K. NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon. Antimicrob. Agents Chemother. 2006, 50, 2976-2982.
21. Mathy, J.E.; Ma, S.; Compton, T.; Lin, K. Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance. Antimicrob. Agents Chemother. 2008, 52, 3267-3275.
22. Hopkins, S.; Scorneaux, B.; Huang, Z.; Murray, M.G.; Wring, S.; Smitley, C.; Harris, R.; Erdmann, F.; Fischer, G.; Ribeill, Y. SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob. Agents Chemother. 2010, 54, 660-672.
23. Watashi, K.; Ishii, N.; Hijikata, M.; Inoue, D.; Murata, T.; Miyanari, Y.; Shimotohno, K. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol. Cell 2005, 19, 111-122.
24. Nakagawa, M.; Sakamoto, N.; Tanabe, Y.; Koyama, T.; Itsui, Y.; Takeda, Y.; Chen, C.H.; Kakinuma, S.; Oooka, S.; Maekawa, S.; Enomoto, N.; Watanabe, M. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology 2005, 129, 1031-1041.
25. Yang, F.; Robotham, J.M.; Nelson, H.B.; Irsigler, A.; Kenworthy, R.; Tang, H. Cyclophilin a is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J. Virol. 2008, 82, 5269-5278.
26. Kaul, A.; Stauffer, S.; Berger, C.; Pertel, T.; Schmitt, J.; Kallis, S.; Zayas, M.; Lohmann, V.; Luban, J.; Bartenschlager, R. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog. 2009, 5, e1000546.
27. Chatterji, U.; Bobardt, M.; Selvarajah, S.; Yang, F.; Tang, H.; Sakamoto, N.; Vuagniaux, G.; Parkinson, T.; Gallay, P. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J. Biol. Chem. 2009, 284, 16998-17005.
28. Ciesek, S.; Steinmann, E.; Wedemeyer, H.; Manns, M.P.; Neyts, J.; Tautz, N.; Madan, V.; Bartenschlager, R.; von Hahn, T.; Pietschmann, T. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Hepatology 2009, 50, 1638-1645.
29. Abe, K.; Ikeda, M.; Ariumi, Y.; Dansako, H.; Wakita, T.; Kato, N. HCV genotype 1b chimeric replicon with NS5B of JFH-1 exhibited resistance to cyclosporine A. Arch. Virol. 2009, 154, 1671-1677.
30. Luban, J.; Bossolt, K.L.; Franke, E.K.; Kalpana, G.V.; Goff, S.P. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 1993, 73, 1067-1078.
31. Braaten, D.; Luban, J. Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells. EMBO J. 2001, 20, 1300-1309.
32. Ke, H.M.; Zydowsky, L.D.; Liu, J.; Walsh, C.T. Crystal structure of recombinant human T-cell cyclophilin A at 2.5 A resolution. Proc. Natl. Acad. Sci. U. S. A. 1991, 88, 9483-9487.
33. Mikol, V.; Kallen, J.; Walkinshaw, M.D. X-ray structure of a cyclophilin B/cyclosporin complex: comparison with cyclophilin A and delineation of its calcineurin-binding domain. Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 5183-5186.
34. Ke, H.; Zhao, Y.; Luo, F.; Weissman, I.; Friedman, J. Crystal structure of murine cyclophilin C complexed with immunosuppressive drug cyclosporin A. Proc. Natl. Acad. Sci. U. S. A. 1993, 90, 11850-11854.
35. Fernandes, F.; Poole, D.S.; Hoover, S.; Middleton, R.; Andrei, A.C.; Gerstner, J.; Striker, R. Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B. Hepatology 2007, 46, 1026-1033.
36. Heck, J.A.; Meng, X.; Frick, D.N. Cyclophilin B stimulates RNA synthesis by the HCV RNA dependent RNA polymerase. Biochem. Pharmacol. 2009, 77, 1173-1180.
37. Robida, J.M.; Nelson, H.B.; Liu, Z.; Tang, H. Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro. J. Virol. 2007, 81, 5829-5840.
38. Handschumacher, R.E.; Harding, M.W.; Rice, J.; Drugge, R.J.; Speicher, D.W. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 1984, 226, 544-547.
39. Takahashi, N.; Hayano, T.; Suzuki, M. Peptidyl-prolyl cis-trans isomerase is the cyclosporin Abinding protein cyclophilin. Nature 1989, 337, 473-475.
40. Fischer, G.; Wittmann-Liebold, B.; Lang, K.; Kiefhaber, T.; Schmid, F.X. Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature 1989, 337, 476-478.
41. Zydowsky, L.D.; Etzkorn, F.A.; Chang, H.Y.; Ferguson, S.B.; Stolz, L.A.; Ho, S.I.; Walsh, C.T. Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition. Protein Sci. 1992, 1, 1092-1099.
42. Liu, Z.; Yang, F.; Robotham, J.M.; Tang, H. Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex. J. Virol. 2009, 83, 6554-6565.
43. Gamble, T.R.; Vajdos, F.F.; Yoo, S.; Worthylake, D.K.; Houseweart, M.; Sundquist, W.I.; Hill, C.P. Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell 1996, 87, 1285-1294.
44. Hanoulle, X.; Badillo, A.; Wieruszeski, J.M.; Verdegem, D.; Landrieu, I.; Bartenschlager, R.; Penin, F.; Lippens, G. Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins A and B. J. Biol. Chem. 2009, 284, 13589-13601.
45. Fernandes, F.; Ansari, I.U.; Striker, R. Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A. PLoS One 2010, 5, e9815.
46. Chatterji, U.; Lim, P.; Bobardt, M.D.; Wieland, S.; Cordek, D.G.; Vuagniaux, G.; Chisari, F.; Cameron, C.E.; Targett-Adams, P.; Parkinson, T.; Gallay, P.A. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. J. Hepatol. 2010.
47. Chatterji, U.; Bobardt, M.D.; Lim, P.; Gallay, P.A. Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes. J. Gen. Virol. 2010, 91, 1189-1193.
48. Quinkert, D.; Bartenschlager, R.; Lohmann, V. Quantitative analysis of the hepatitis C virus replication complex. J. Virol. 2005, 79, 13594-13605.
49. Goto, K.; Watashi, K.; Murata, T.; Hishiki, T.; Hijikata, M.; Shimotohno, K. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. Biochem. Biophys. Res. Commun. 2006, 343, 879-884.
50. Landrieu, I.; Hanoulle, X.; Bonachera, F.; Hamel, A.; Sibille, N.; Yin, Y.; Wieruszeski, J.M.; Horvath, D.; Wei, Q.; Vuagniaux, G.; Lippens, G. Structural basis for the non-immunosuppressive character of the cyclosporin A analogue Debio 025. Biochemistry 2010, 49, 4679-4686.
51. Sadeg, N.; Pham-Huy, C.; Rucay, P.; Righenzi, S.; Halle-Pannenko, O.; Claude, J.R.; Bismuth, H.; Duc, H.T. In vitro and in vivo comparative studies on immunosuppressive properties of cyclosporines A, C, D and metabolites M1, M17 and M21. Immunopharmacol. Immunotoxicol. 1993, 15, 163-177.
52. Flisiak, R.; Horban, A.; Gallay, P.; Bobardt, M.; Selvarajah, S.; Wiercinska-Drapalo, A.; Siwak, E.; Cielniak, I.; Higersberger, J.; Kierkus, J.; Aeschlimann, C.; Grosgurin, P.; Nicolas-Metral, V.; Dumont, J.M.; Porchet, H.; Crabbe, R.; Scalfaro, P. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 2008, 47, 817-826.
53. Blight, K.J.; McKeating, J.A.; Rice, C.M. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 2002, 76, 13001-13014.
54. Mercer, D.F.; Schiller, D.E.; Elliott, J.F.; Douglas, D.N.; Hao, C.; Rinfret, A.; Addison, W.R.; Fischer, K.P.; Churchill, T.A.; Lakey, J.R.; Tyrrell, D.L.; Kneteman, N.M. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 2001, 7, 927-933.
55. Rosenwirth, B.; Billich, A.; Datema, R.; Donatsch, P.; Hammerschmid, F.; Harrison, R.; Hiestand, P.; Jaksche, H.; Mayer, P.; Peichl, P.; et al. Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. Antimicrob. Agents Chemother. 1994, 38, 1763-1772.
56. Hopkins, S., D. Heuman, E. Gavis, J. Lalezari, E. Glutzer, B. DiMassimo, P. Rusnak, S. Wring, C. Smitley, and Y. Ribeill. Safety, plasma, pharmacokinetics, and anti-viral activity of SCY-635 in adult patients with chronic hepatitis C virus infection. J. Hepatology 2009, 50, S36.
57. Jeffery, J.R. Cyclosporine analogues. Clin. Biochem. 1991, 24, 15-21.
58. Goto, K.; Watashi, K.; Inoue, D.; Hijikata, M.; Shimotohno, K. Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor. Cancer Sci. 2009, 100, 1943-1950.
59. Puyang, X.; Poulin, D.L.; Mathy, J.E.; Anderson, L.J.; Ma, S.; Fang, Z.; Zhu, S.; Lin, K.; Fujimoto, R.; Compton, T.; Wiedmann, B. Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors. Antimicrob. Agents Chemother. 2010, 54, 1981-1987.
60. Zhang, L.H.; Liu, J.O. Sanglifehrin A, a novel cyclophilin-binding immunosuppressant, inhibits IL-2-dependent T cell proliferation at the G1 phase of the cell cycle. J. Immunol. 2001, 166, 5611-5618.
61. Zenke, G.; Strittmatter, U.; Fuchs, S.; Quesniaux, V.F.; Brinkmann, V.; Schuler, W.; Zurini, M.; Enz, A.; Billich, A.; Sanglier, J.J.; Fehr, T. Sanglifehrin A, a novel cyclophilin-binding compound showing immunosuppressive activity with a new mechanism of action. J. Immunol. 2001, 166, 7165-7171.
62. Rong, L.; Dahari, H.; Ribeiro, R.M.; Perelson, A.S. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci. Transl. Med. 2, 30-32.
63. Yang, F.; Robotham, J.M.; Grise, H.; Frausto, S.; Madan, V.; Zayas, M.; Bartenschlager, R.; Robinson, M.; Greenstein, A.E.; Nag, A.; Logan, T.; Bienkiewicz, E.; Tang, H. A Major Determinant of Cyclophilin Dependence and Cyclosporine Susceptibility of Hepatitis C Virus Identified by a Genetic Approach. PLoS Pathog. 2010, in press.
64. Moradpour, D.; Evans, M.J.; Gosert, R.; Yuan, Z.; Blum, H.E.; Goff, S.P.; Lindenbach, B.D.; Rice, C.M. Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J. Virol. 2004, 78, 7400-7409.
65. Nelson, H.B.; Tang, H. Effect of cell growth on hepatitis C virus (HCV) replication and a mechanism of cell confluence-based inhibition of HCV RNA and protein expression. J. Virol. 2006, 80, 1181-1190.
66. Pfeiffer, J.K.; Kirkegaard, K. Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA. J. Virol. 2005, 79, 2346-2355.
67. Liu, Z.; Robida, J.M.; Chinnaswamy, S.; Yi, G.; Robotham, J.M.; Nelson, H.B.; Irsigler, A.; Kao, C.C.; Tang, H. Mutations in the hepatitis C virus polymerase that increase RNA binding can confer resistance to cyclosporine A. Hepatology 2009, 50, 25-33.
68. Gao, M.; Nettles, R.E.; Belema, M.; Snyder, L.B.; Nguyen, V.N.; Fridell, R.A.; Serrano-Wu, M.H.; Langley, D.R.; Sun, J.H.; O'Boyle, D.R., 2nd; Lemm, J.A.; Wang, C.; Knipe, J.O.; Chien, C.; Colonno, R.J.; Grasela, D.M.; Meanwell, N.A.; Hamann, L.G. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature, 465, 96-100.
69. Ishii, N.; Watashi, K.; Hishiki, T.; Goto, K.; Inoue, D.; Hijikata, M.; Wakita, T.; Kato, N.; Shimotohno, K. Diverse effects of cyclosporine on hepatitis C virus strain replication. J. Virol. 2006, 80, 4510-4520.
70. Gallay, P.A. Cyclophilin inhibitors. Clin. Liver Dis. 2009, 13, 403-417.
71. Colgan, J.; Asmal, M.; Neagu, M.; Yu, B.; Schneidkraut, J.; Lee, Y.; Sokolskaja, E.; Andreotti, A.; Luban, J. Cyclophilin A regulates TCR signal strength in CD4+ T cells via a proline-directed conformational switch in Itk. Immunity 2004, 21, 189-201.